MGMT and glioblastoma: Overexpression of HOXD-AS2 is indicative of an unfavorable prognosis in glioma patients, and its upregulation promotes resistance to temozolomide, enhances MGMT expression, and reinforces the invasiveness of glioblastoma cells 36, 37.